SOURCE: MYOS Corporation

MYOS Corporation

March 30, 2015 07:35 ET

MYOS Corporation Announces the Re Muscle Health™ Series Powered by Fortetropin®

Company Launches the World's First All Natural, Non-GMO Bio-Nutritional Product Line Harnessing Stem Cell Science to Build Healthy Lean Muscle

CEDAR KNOLLS, NJ--(Marketwired - Mar 30, 2015) -  MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the launch of its new product line, Rē Muscle Health™, providing non-GMO protein bars, shakes, pudding mixes and ready to eat powders. Rē Muscle Health™ products help rebuild, rejuvenate and maintain lean muscle and are designed for individuals who want an all-natural product with clinically proven results. 

Fortetropin®, the active ingredient in Rē Muscle Health™, is clinically proven to build healthy lean muscle. It accomplishes this through a fertilized egg based protein and lipid complex that increases protein synthesis and inhibits muscle degradation pathways while naturally reducing serum myostatin activity. Myostatin is a major regulator of muscle size and functionality. Rē Muscle Health™ also has 20 grams of protein to help protect, preserve and promote healthy lean muscle. Rē Muscle Health™ Bars, powders and meal replacement shakes can be used daily:

  • To increase both muscle thickness and lean body mass
  • For workout recovery -- protein helps promote muscle recovery and growth
  • As a snack or meal replacement

The Rē Muscle Health™ Series comes in six flavors, and can be Pre-ordered online at  

Doug Weekes, Chief Commercial Officer of MYOS, commented, "We are proud to launch Rē Muscle Health™, a new brand designed to Rebuild, Rejuvenate, and deliver muscle health Results. Rē Muscle Health™ has the potential to revolutionize the way consumers prevent the inevitable muscle loss that accompanies aging. The products taste great, use only non-GMO ingredients, and deliver the added benefit of muscle health. Our marketing in the coming year will focus on driving product trials and raising awareness through event marketing, sampling, and social media. will introduce people to Rē Muscle Health™ and educate them on sarcopenia, age related muscle loss and other acute muscle diseases."

Chairman of MYOS, Dr. Robert Hariri, added, "It is becoming increasingly apparent that muscle is a master regulatory tissue which is critical to metabolic and physiologic stability. Building and maintaining lean muscle mass is one of the most important and actionable aspects of preserving good health. MYOS discovered fertilized chicken eggs were a source of stem cell proteins and lipids. The daily use of Fortetropin® has been clinically proven to improve lean muscle mass in conjunction with exercise. The results of the clinical trials conducted with Fortetropin® demonstrated statistically significant increases in strength and power end points as measured by bench press, leg press and wingate power. We encourage consumers to visit, in order to purchase products that will help turn back the individual's muscle health clock.

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit

About Rē Muscle Health™
The Rē Muscle Health™ series is the Company's first branded line of muscle health products. This unique line of all-natural, non-GMO products contain Fortetropin®, an egg-based, all natural myostatin inhibitor clinically proven to build healthy muscle. The Rē Muscle Health™ series can be Pre-ordered by visiting MYOS believes that Fortetropin®, as well as future products it envisions, will redefine existing standards for muscle health. The Rē Muscle Health™ product line is owned and sold directly by the Company.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our Rē Muscle Health™ and other products, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully launch our own Rē Muscle Health™ products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin® and Rē Muscle Health™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Contact Information

  • MYOS Corporation Investor and Media Contact:

    Lindsey Penrose
    Vice President Business Development
    (973) 509-0444
    Email Contact